Drugs / allo-APZ2-DFU
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03267784 | Nov 2017 → Jun 2020 | chronic ulcer of skin | RHEACELL GmbH & Co. KG | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | allo-APZ2-DFU | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03267784 ↗ |
| Modality | Cell therapy | “allogeneic ABCB5-positive mesenchymal stem cells (MSCs)” NCT03267784 ↗ |
| Route | Topical | “topically administered to the wound matrix” NCT03267784 ↗ |